Median effective dose of remazolam besilate in combination with different doses of esketamine for painless gastroscopy:A randomized controlled, double-blind, prospective study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300068488

Enrollment

Unknown

Registered

2023-02-21

Start date

2023-03-01

Completion date

Unknown

Last updated

2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastrointestinal endoscopy

Interventions

Esketamine 0mg group:Induction of anesthesia using 0mg esketamine combined with remazolam besylate

Esketamine 0.2mg/kg group:Induction of anesthesia using 0.2mg/kg esketamine combined with remazolam besylate

Esketamine 0.4mg/kg group:Induction of anesthesia using 0.4mg/kg esketamine combined with remazolam besylate

Esketamine 0.6mg/kg group :Induction of anesthesia using 0.6mg/kg esketamine combined with remazolam besylate

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-65 years old; 2. Body mass index 19-28kg/m^2; 3. ASA I-III grade; 4. All selected participants agree to participate in this research and sign.

Exclusion criteria

Exclusion criteria: 1. Acute heart failure, unstable angina, myocardial infarction within 6 months, resting electrocardiogram (ECG) heart rate = 180 mmHg or diastolic blood pressure >= 90 mmHg 3. Acute respiratory infection, acute exacerbation of COPD, poorly controlled asthma 4. End-stage renal failure and hepatic decompensation 5. Mental disorders include: schizophrenia, mania, bipolar disorder, or cognitive dysfunction 6. Those who are allergic to benzodiazepines or ketamine 7. Those who have taken benzodiazepines in the past 3 months or have a history of general anesthesia surgery 8. Complicated endoscopic operations, such as gastric polypectomy, etc. 9. Pregnant and lactating women 10. Unable to cooperate with psychosocial problems and other reasons.

Design outcomes

Primary

Measure	Time frame
median effective dose;	—

Secondary

Measure	Time frame
anesthesia induction time;operation time;Anesthesia recovery time;Anesthetic dosage;Endoscopy physician satisfaction;patient satisfaction;adverse reactions;	—

Countries

China

Contacts

Public ContactLi Linji

Department of Anesthesiology, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College

llj-stwphen@163.com+86 152 2815 2382

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026